- Nearly half of patients who received support through a patient engagement tool prior to a cardiology clinic visit had a positive change in their medication therapy compared to less than a third among patients who did not receive the engagement tool.
- The most common medication change was to increase the dose of generic medications already prescribed.
- A similar method of patient engagement may be used to improve treatment of other chronic diseases that include complex medication regimens and options.
Embargoed until 12:06 p.m. CT/1:06 p.m. ET, Tuesday, Nov. 17, 2020
DALLAS, Nov. 17, 2020 — A novel patient engagement tool led one in five patients with heart failure to a more effective treatment regimen of generic medications, according to late- breaking research presented today at the American Heart Association’s Scientific Sessions 2020. The meeting is virtual, Friday, November 13-Tuesday, November 17, 2020, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care. The manuscript for this study is published simultaneously today in Circulation, the American Heart Association’s flagship journal.
In the study, “Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial,” patients were randomized into two groups – those who had a regularly scheduled cardiology clinic visit versus those who received an additional engagement and education tool before the visit. The patients assigned to the patient engagement tool, called EPIC-HF, received access to a three-minute video and a one-page checklist, delivered electronically by text or email, at one week, three days and 24 hours prior to a cardiology clinic visit .
Patients with heart failure with reduced ejection fraction (HFrEF) have a weak left ventricle, so the body is receiving less blood than needed. Multiple medications have been shown to improve heart function, and when used together at doses that can help them meet treatment goals, these medicines may help people with HFrEF feel better, live longer and improve their condition. Unfortunately, most people with HFrEF are not getting all of medications at the right doses. Often, the ones prescribed are dosed too low.
EPIC-HF’s goal was to help patients understand their medication options and encourage them to collaborate with their health care professionals to “make one positive change” in their HFrEF treatment.
Research analyzed the outcomes of 290 patients, of whom half received the patient EPIC-HF education tools. Average patient age was 65 years, and 29% were female. Average left ventricular ejection fraction was 32%. At the beginning of the study, none of the 290 patients were receiving optimal HFrEF treatment (current standard of care for HFrEF includes goal doses of a beta-blocker; sacubitril/valsartan; and spironolactone or eplerenone).
The study’s results show:
- Nearly half (49%) of the EPIC-HF intervention group had a change in their medications for HFrEF to improve therapy compared to 29.7% in the control group.
- Most changes were increases in the doses of generic HFrEF medications already prescribed, not new medications.
- Increase in medication doses did not cause obvious problems in the 30 days after the clinical visit.
“We are pleasantly surprised that this fairly simple tool lead so many patients to better care. It’s promising that patients were able get better treatment,” said the lead study author Larry A. Allen, M.D., M.H.S., the associate division head for Clinical Affairs in Cardiology and co-director of the Colorado Program for Patient-Centered Decision at the University of Colorado School of Medicine in Aurora, Colorado. “This approach validates and promotes a culture of collaboration between patients and their doctors and leads to more productive clinic visits with optimized medication prescribing, which can ultimately improve patient outcomes.”
The researchers believe patient-centered tools that inform and encourage people to become active participants in their health will improve overall care and outcomes.
Co-authors are Grace E. Venchuk, M.A.; Prateeti Khazanie, M.D.; Robert L. Page II, Pharm.D.; Christopher E. Knoepke, M.S.W., Ph.D.; Laura J. Helmkamp, M.S.; Colleen K. McIlvennan, Ph.D., D.N.P.; Pamela N. Petersen, M.D.; Kenneth Pierce, B.A.; Jocelyn S. Thompson, M.A.; Janice V. Huang, M.D.; James Strader, M.D.; Tristan J. Dow, M.D.; Lance C. Richards, D.O.; Katy E. Trinkley, Pharm.D., Ph.D.; David P. Kao, M.D.; David J. Magid, M.D.; Peter M. Buttrick, M.D.; and Daniel D. Matlock, M.D.
The study was funded by the American Heart Association’s Strategically Focused Research Network.
Presentation: Session: LBS09 High Tech or High Touch: Creative Strategies to Optimize Patient Care
- Multimedia is available on the right column of the release link https://newsroom.heart.org/news/patient-engagement-program-for-heart-failure-patients-improved-outcomes?preview=ec7ab307b113ab086512bff87bd5b5d8
- Palliative care for heart failure patients may lower rehospitalization risk and improve outcomes
- For more news at AHA Scientific Sessions 2020, follow us on Twitter @HeartNews
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers are available here, and the Association’s overall financial information is available here.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective:
AHA News Media in Dallas: 214-706-1173; email@example.com
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org